 Graft vs Host Disease
"Graft vs Host Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
| Descriptor ID |
D006086
|
| MeSH Number(s) |
C20.452
|
| Concept/Terms |
Graft vs Host Disease- Graft vs Host Disease
- Graft-Versus-Host Disease
- Disease, Graft-Versus-Host
- Diseases, Graft-Versus-Host
- Graft Versus Host Disease
- Graft-Versus-Host Diseases
- Runt Disease
- Disease, Runt
- Graft-vs-Host Disease
- Disease, Graft-vs-Host
- Diseases, Graft-vs-Host
- Graft-vs-Host Diseases
- Homologous Wasting Disease
- Disease, Homologous Wasting
|
Below are MeSH descriptors whose meaning is more general than "Graft vs Host Disease".
Below are MeSH descriptors whose meaning is more specific than "Graft vs Host Disease".
This graph shows the total number of publications written about "Graft vs Host Disease" by people in this website by year, and whether "Graft vs Host Disease" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 0 | 1 | 1 | | 1993 | 1 | 0 | 1 | | 1994 | 2 | 0 | 2 | | 1996 | 0 | 1 | 1 | | 1997 | 2 | 2 | 4 | | 1998 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2001 | 3 | 0 | 3 | | 2002 | 0 | 2 | 2 | | 2003 | 1 | 0 | 1 | | 2004 | 3 | 1 | 4 | | 2005 | 1 | 4 | 5 | | 2006 | 2 | 2 | 4 | | 2007 | 3 | 3 | 6 | | 2008 | 1 | 2 | 3 | | 2009 | 4 | 5 | 9 | | 2010 | 2 | 3 | 5 | | 2011 | 4 | 4 | 8 | | 2012 | 3 | 4 | 7 | | 2013 | 4 | 0 | 4 | | 2014 | 3 | 6 | 9 | | 2015 | 7 | 3 | 10 | | 2016 | 7 | 4 | 11 | | 2017 | 4 | 3 | 7 | | 2018 | 6 | 5 | 11 | | 2019 | 5 | 3 | 8 | | 2020 | 7 | 0 | 7 | | 2021 | 4 | 0 | 4 | | 2022 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Graft vs Host Disease" by people in Profiles.
-
Phelan R, Im A, Hunter RL, Inamoto Y, Lupo-Stanghellini MT, Rovo A, Badawy SM, Burns L, Eissa H, Murthy HS, Prasad P, Sharma A, Suelzer E, Agrawal V, Aljurf M, Baker K, Basak GW, Buchbinder D, DeFilipp Z, Grkovic LD, Dias A, Einsele H, Eisenberg ML, Epperla N, Farhadfar N, Flatau A, Gale RP, Greinix H, Hamilton BK, Hashmi S, Hematti P, Jamani K, Maharaj D, Murray J, Naik S, Nathan S, Pavletic S, Peric Z, Pulanic D, Ross R, Salonia A, Sanchez-Ortega I, Savani BN, Schechter T, Shah AJ, Smith SM, Snowden JA, Steinberg A, Tremblay D, Vij SC, Walker L, Wolff D, Yared JA, Schoemans H, Tichelli A. Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Bone Marrow Transplant. 2022 07; 57(7):1150-1163.
-
Qayed M, Watkins B, Gillespie S, Bratrude B, Betz K, Choi SW, Davis J, Duncan C, Giller R, Grimley M, Harris AC, Jacobsohn D, Lalefar N, Norkin M, Farhadfar N, Pulsipher MA, Shenoy S, Petrovic A, Schultz KR, Yanik GA, Waller EK, Langston A, Kean LS, Horan JT. Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation. Blood Adv. 2022 02 08; 6(3):746-749.
-
Liao SY, Gerber AN, Zelarney P, Make B, Wechsler ME. Impaired SARS-CoV-2 mRNA Vaccine Antibody Response in Chronic Medical Conditions: A Real-World Analysis. Chest. 2022 06; 161(6):1490-1493.
-
Yeh J, Whited L, Saliba RM, Rondon G, Banchs J, Shpall E, Champlin R, Popat U. Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era. Blood Adv. 2021 12 28; 5(24):5599-5607.
-
Sharma A, Huang S, Li Y, Brooke RJ, Ahmed I, Allewelt HB, Amrolia P, Bertaina A, Bhatt NS, Bierings MB, Bies J, Brisset C, Brondon JE, Dahlberg A, Dalle JH, Eissa H, Fahd M, Gassas A, Gloude NJ, Goebel WS, Goeckerman ES, Harris K, Ho R, Hudspeth MP, Huo JS, Jacobsohn D, Kasow KA, Katsanis E, Kaviany S, Keating AK, Kernan NA, Ktena YP, Lauhan CR, López-Hernandez G, Martin PL, Myers KC, Naik S, Olaya-Vargas A, Onishi T, Radhi M, Ramachandran S, Ramos K, Rangarajan HG, Roehrs PA, Sampson ME, Shaw PJ, Skiles JL, Somers K, Symons HJ, de Tersant M, Uber AN, Versluys B, Cheng C, Triplett BM. Outcomes of pediatric patients with therapy-related myeloid neoplasms. Bone Marrow Transplant. 2021 12; 56(12):2997-3007.
-
Thangavelu G, Wang C, Loschi M, Saha A, Osborn MJ, Furlan SN, Aoyama K, McDonald-Hyman C, Aguilar EG, Janesick AS, Chandraratna RA, Refaeli Y, Panoskaltsis-Mortari A, MacDonald KP, Hill GR, Zeiser R, Maillard I, Serody JS, Murphy WJ, Munn DH, Blumberg B, Brown C, Kuchroo V, Kean LS, Hippen KL, Noelle RJ, Blazar BR. Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses. Blood. 2021 02 25; 137(8):1090-1103.
-
Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y, Yu A, Sinclair S, Furlan S, Bosinger S, Tkachev V, Rhodes J, Tumlin AG, Narayan A, Cribbin K, Gillespie S, Gooley TA, Pasquini MC, Hebert K, Kapoor U, Rogatko A, Tighiouart M, Kim S, Bresee C, Choi SW, Davis J, Duncan C, Giller R, Grimley M, Harris AC, Jacobsohn D, Lalefar N, Norkin M, Farhadfar N, Pulsipher MA, Shenoy S, Petrovic A, Schultz KR, Yanik GA, Waller EK, Levine JE, Ferrara JL, Blazar BR, Langston A, Horan JT, Kean LS. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. J Clin Oncol. 2021 06 10; 39(17):1865-1877.
-
Solomon SR, Aubrey MT, Zhang X, Jackson KC, Morris LE, Holland HK, Solh MM, Bashey A. Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide. Blood Adv. 2020 10 27; 4(20):5311-5321.
-
Roeker LE, Dreger P, Brown JR, Lahoud OB, Eyre TA, Brander DM, Skarbnik A, Coombs CC, Kim HT, Davids M, Manchini ST, George G, Shah N, Voorhees TJ, Orchard KH, Walter HS, Arumainathan AK, Sitlinger A, Park JH, Geyer MB, Zelenetz AD, Sauter CS, Giralt SA, Perales MA, Mato AR. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv. 2020 08 25; 4(16):3977-3989.
-
George G, Martin AS, Chhabra S, Eapen M. The Effect of Granulocyte Colony-Stimulating Factor Use on Hospital Length of Stay after Allogeneic Hematopoietic Cell Transplantation: A Retrospective Multicenter Cohort Study. Biol Blood Marrow Transplant. 2020 12; 26(12):2359-2364.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|